ReviewBritish journal of cancer2020
Current and novel therapeutic opportunities for systemic therapy in biliary cancer.
Review in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.The Cochrane database of systematic reviews · 2021Pooled it
- Adjuvant tislelizumab, lenvatinib, and capecitabine for resected biliary tract cancer: a prospective phase II trial.BMC medicine · 2026Trial
- The instructive scar - the dynamic role of extracellular matrix in biliary pathophysiology.Disease models & mechanisms · 2026Review
- Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors.Cancer research communications · 2026Article
- Primary signet-ring cell carcinoma of the bile duct: clinical characteristics, survival comparison with cholangiocarcinoma, and SEER-based prognostic nomograms.Translational cancer research · 2025Article
- Methylation aberrations and genomic instability synergistically drive the evolution of intrahepatic cholangiocarcinoma.Epigenomics · 2025Article
- Cholangiocarcinoma: The era of liquid biopsy.World journal of gastroenterology · 2025Review
- Efficacy of lenvatinib combined with TAS-102 as second-line therapy for advanced intrahepatic cholangiocarcinoma: a case report.Frontiers in oncology · 2025Article
- Targeting the gut-liver axis in cholangiocarcinoma: mechanisms, therapeutic advances, and future directions.Frontiers in oncology · 2025Review
- Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic.BMC cancer · 2024Article
- Macro CD5LNature communications · 2024Article
- Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2024Article
- Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case.Frontiers in oncology · 2024Article
- Article
- Article
- Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers.Cancers · 2022Review
- Article
- Article
- Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer.JHEP reports : innovation in hepatology · 2022Article
- Prognostic value of Dickkopf-1 and ß-catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer.Scientific reports · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
25 authors at 16 institutions in 6 countries.
Funding
Abstract
Biliary tract cancers (BTCs) are a group of rare and aggressive malignancies that arise in the biliary tree within and outside the liver. Beyond surgical resection, which is beneficial for only a small proportion of patients, current strategies for treating patients with BTCs include chemotherapy, as a single agent or combination regimens, in the adjuvant and palliative setting. Increased characterisation of the molecular landscape of these tumours has facilitated the identification of molecular vulnerabilities, such as IDH mutations and FGFR fusions, that can be exploited for the treatment of BTC patients. Beyond targeted therapies, active research avenues explore the development of novel therapeutics that target the crosstalk between cancer and stroma, the cellular pathways involved in the regulation of cell death, the chemoresistance phenotype and the dysregulation of RNA. In this review, we discuss the therapeutic opportunities currently available in the management of BTC patients, and explore the strategies that can support the implementation of precision oncology in BTCs, including novel molecular targets, liquid biopsies and patient-derived predictive tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.